Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores

por Broekman, K.E., van Kruchten, M., van Tinteren, H., Sessa, C., Jalving, M., Reyners, A.K.L.
Publicado 2021

Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer

por Ismail, R.K., van Breeschoten, J., Wouters, M.W.J.M., van Dartel, M., van der Flier, S., Reyners, A.K.L., de Graeff, P., Pasmooij, A.M.G., de Boer, A., Broekman, K.E., Hilarius, D.L.
Publicado 2021

Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions?

por Ismail, R.K., van Breeschoten, J., Wouters, M.W.J.M., van Dartel, M., van der Flier, S., Reyners, A.K.L., de Graeff, P., Pasmooij, A.M.G., de Boer, A., Broekman, K.E., Hilarius, D.L.
Publicado 2022